# OnCo record monte-rosa (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/monte-rosa/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "monte-rosa" ;
  schema:name "Monte Rosa Therapeutics"@en ;
  schema:description "Molecular-glue degrader company with a GSPT1 degrader in phase 2 for AR-mutant prostate cancer and a CCNE1-directed glue in preclinical development."@en ;
  schema:url <https://onco.cc/companies/monte-rosa/>, <https://www.monterosatx.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.globenewswire.com/news-release/2026/08/24/3349601/0/en/monte-rosa-therapeutics-announces-first-patient-dosed-in-modefire-1-a-phase-2-study-of-mrt-2359-in-combination-with-apalutamide-in-patients-with-ar-mutation-positive-metastatic-cas.html> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/ovarian/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/protac-degrader/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/roche-genentech/> ;
  onco:trials <https://onco.cc/trials/nct07745361/>, <https://onco.cc/trials/nct05546268/> .